Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PharmAla completes historic first shipment of MDMA from Canada to USA for use in a UCLA Clinical Trial
-
PharmAla to supply the STRONG STAR Consortium with new 20mg MDMA dose to treat active-duty military personnel in a clinical trial
-
PharmAla adds Matthew Azrieli to Advisory Team
-
PharmAla releases its Q1 financial statements
-
PharmAla partners with Merhavim and MAPS Israel for innovative MDMA PTSD clinical trial data sharing partnership in wake of Gaza Ceasefire
-
PharmAla files audited financials for year ended August 31, 2024, completes continuance and oversubscribed private placement
-
PharmAla announces private placement financing
-
PharmAla reaches agreement in principle to trade with a clinical trial to trade its LaNeo MDMA for a data license to the trial outcomes.
-
PharmAla to supply Yale University with MDMA for clinical trial
-
PharmAla contracted to sell MDMA to Mt. Sinai Hospital, NY. Terminates Contract with CCrest Labs.